CA2433384A1 - Analogues de tacrolimus neurotrophiques - Google Patents

Analogues de tacrolimus neurotrophiques Download PDF

Info

Publication number
CA2433384A1
CA2433384A1 CA002433384A CA2433384A CA2433384A1 CA 2433384 A1 CA2433384 A1 CA 2433384A1 CA 002433384 A CA002433384 A CA 002433384A CA 2433384 A CA2433384 A CA 2433384A CA 2433384 A1 CA2433384 A1 CA 2433384A1
Authority
CA
Canada
Prior art keywords
compound
injury
nerve
spinal cord
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002433384A
Other languages
English (en)
Inventor
Nobuya Matsuoka
Takayuki Yamaji
Bruce Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2433384A1 publication Critical patent/CA2433384A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des dérivés de tacrolimus présentant des niveaux élevés d'activité neurotrophique et de faibles niveaux d'activité immunosuppressive. Ces composés constituent des agents neurotrophiques très utiles, en particulier dans la prévention ou le traitement d'une lésion/dysfonction neuronale.
CA002433384A 2000-12-29 2001-12-31 Analogues de tacrolimus neurotrophiques Abandoned CA2433384A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25850000P 2000-12-29 2000-12-29
US60/258,500 2000-12-29
PCT/US2001/050419 WO2002053159A1 (fr) 2000-12-29 2001-12-31 Analogues de tacrolimus neurotrophiques

Publications (1)

Publication Number Publication Date
CA2433384A1 true CA2433384A1 (fr) 2002-07-11

Family

ID=22980816

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002433384A Abandoned CA2433384A1 (fr) 2000-12-29 2001-12-31 Analogues de tacrolimus neurotrophiques

Country Status (18)

Country Link
EP (1) EP1353671A4 (fr)
JP (1) JP2004527472A (fr)
KR (2) KR100794204B1 (fr)
CN (1) CN1293877C (fr)
AR (1) AR035411A1 (fr)
AU (1) AU2002231277B2 (fr)
BR (1) BR0116762A (fr)
CA (1) CA2433384A1 (fr)
CZ (1) CZ20032060A3 (fr)
HU (1) HUP0302521A3 (fr)
IL (1) IL156664A0 (fr)
MX (1) MXPA03005941A (fr)
NO (1) NO20032913D0 (fr)
NZ (1) NZ527209A (fr)
PL (1) PL366301A1 (fr)
RU (1) RU2288716C2 (fr)
WO (1) WO2002053159A1 (fr)
ZA (1) ZA200305806B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901023A0 (en) * 2003-03-04 2003-03-20 Fujisawa Pharmaceutical Co., Ltd. New use
JP2007518692A (ja) * 2004-01-20 2007-07-12 アステラス製薬株式会社 勃起不全治療方法
EP1810675A1 (fr) * 2006-01-18 2007-07-25 Institut Curie Methode de traitement de la maladie de Huntington par l'inhibition de la dephosphorylation de la S421
JP2009102226A (ja) * 2006-02-14 2009-05-14 Meiji Milk Prod Co Ltd 脊髄損傷治療剤
CA2730751A1 (fr) * 2008-07-23 2010-01-28 Novartis Ag Modulateurs du recepteur de sphingosine 1 phosphate et leur utilisation pour le traitement de l'inflammation musculaire
EP2817009A1 (fr) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Inhibiteurs de la calcineurine destinés à être utilisés dans le traitement des troubles vestibulaires entraînant des lésions
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2799208B2 (ja) * 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
GB9202196D0 (en) * 1992-02-01 1992-03-18 Fisons Plc Method of treatment
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use

Also Published As

Publication number Publication date
EP1353671A1 (fr) 2003-10-22
KR100794204B1 (ko) 2008-01-14
NO20032913D0 (no) 2003-06-24
AR035411A1 (es) 2004-05-26
HUP0302521A3 (en) 2007-03-28
AU2002231277B2 (en) 2006-11-30
KR20070030331A (ko) 2007-03-15
CN1538843A (zh) 2004-10-20
JP2004527472A (ja) 2004-09-09
ZA200305806B (en) 2005-01-26
EP1353671A4 (fr) 2004-07-14
NZ527209A (en) 2005-09-30
CN1293877C (zh) 2007-01-10
RU2288716C2 (ru) 2006-12-10
HUP0302521A2 (hu) 2003-11-28
RU2003123493A (ru) 2005-01-20
MXPA03005941A (es) 2005-02-14
CZ20032060A3 (cs) 2004-01-14
KR20040007431A (ko) 2004-01-24
IL156664A0 (en) 2004-01-04
PL366301A1 (en) 2005-01-24
WO2002053159A1 (fr) 2002-07-11
BR0116762A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
Cui et al. CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters.
Gaviria et al. Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats
KR100298808B1 (ko) 외상손상과관련된신경학적병변의치료를위한,릴루졸을포함하는제약학적조성물
MX2009002063A (es) Tratamiento de desordenes en cartilagos con factor de crecimiento de fibroblastos-18.
LT4516B (lt) Rotamazės fermento inhibitoriai
US20140121221A1 (en) Selective pde4 b inhibition and improvement in cognition in subjects with brain injury
DE69635754T2 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
KR20010032357A (ko) 신경 퇴화의 예방 및 신경 재생의 촉진을 위한 치환된아미노메틸 크로만의 용도
JP6763533B2 (ja) 神経系疾患治療剤
AU2002231277B2 (en) Neurotrophic tacrolimus analogs
AU2002231277A1 (en) Neurotrophic tacrolimus analogs
CN1310622A (zh) 丙戊酸类似物在治疗和预防偏头痛与情感性疾病中的应用
US20040077676A1 (en) Neurotrophic tacrolimus analogs
Hitzenberger et al. Pharmacological properties of piracetam: Rationale for use in stroke patients
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物
Itoh et al. The effect of neurotrophic pyrimidine heterocyclic compounds, MS-818 and MS-430, on the regeneration of injured peripheral nerves
CA2455896A1 (fr) Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil
US6852496B1 (en) Methods of screening for agents that promote nerve cell growth
US6476001B1 (en) Facilitation of repair of neural injury with CM101/GBS toxin
WO2005009359A2 (fr) Agents, compositions et procedes d'amelioration de la fonction neurologique
US20040162315A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
Tessler et al. Neural transplantation: Spinal cord
US20180311191A1 (en) New combination therapies for treating neurological damage
MXPA00002395A (en) Method of increasing bone volume
MXPA97009163A (en) The use of a dopamine / proluctine reduction compound to prepare compositions to prevent associated stenosis with intervention after invasive interventions without deriva

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued